NVO logo

NVONovo Nordisk A/S

$41.11
$1.94
(4.52%)
Today
Closed $41.02
$0.0904
(0.22%)
After Hours
Updated: 06:46 PM EDT
EarningsAug 5
Mkt Cap$144.74B
Vol20.67M
News
all
press releases
LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
Lilly’s Foundayo outperformed existing treatments on blood sugar control and weight loss in type 2 diabetes patients in three late-stage trials.
Stocktwits
News Placeholder
More News
News Placeholder
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
Key PointsZealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients...
Nasdaq News: Markets
News Placeholder
ALT and the Rise of Dual Agonists Targeting Liver Disease
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
Zacks
News Placeholder
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
Zacks
News Placeholder
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
Zacks
News Placeholder
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
Zacks
News Placeholder
Novo Nordisk Real-World Data Supports Ozempic Against LLY's Mounjaro
NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.
Zacks
News Placeholder
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare...
CNBC: Business
News Placeholder
Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?
NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.
Zacks
News Placeholder
Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs
Novo Nordisk reported positive diabetes and weight-loss data, advanced zenagamtide plans, and topped 3 million Wegovy pill prescriptions.read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.